DEEP EXPERIENCE. SHARED COMMITMENT.
"We take a private equity approach to a sector that’s traditionally been dominated by venture and early-stage growth firms. We'll work very closely with management to improve the operations of the business, update the product portfolio and revamp the commercial organization. We provide the support and resources our portfolio companies need to succeed.”
21
active portfolio companies
+
2000
employees worldwide
7
AP-II Investments to Date
9
successful exits
news
Aug 07, 2025
Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia
- CT-155 showed a reduction in experiential negative symptoms as an adjunct to standard of care antipsychotic therapy from baseline to week 16, as measured by CAINS-MAP.
- CT-155 is an investigational prescription digital therapeutic being evaluated to target negative symptoms of schizophrenia in a registrational randomized clinical trial.1,2
- Often underappreciated and less recognized, negative symptoms impact more than half of people living with schizophrenia.3
Jul 29, 2025
Axonius Acquires Medical Device Security Specialist Cynerio for More Than $100 Million to Target Healthcare MarketMove enables $2.6 billion cybersecurity unicorn to secure connected medical devices and protect patient care
Jun 18, 2025
Bioness Medical Announces Acquisition of the Assets and Business of Harmonic BionicsAccelmed portfolio company Bioness Medical, Inc. announced the acquisition of the assets and business of Harmonic Bionics, a robotics company focused on improving neuro rehabilitation patient upper extremity mobility and function deficits.
This marks Bioness Medical's first acquisition since becoming an independent neuro rehabilitation company following its acquisition by Accelmed on December 31, 2024.
Jun 02, 2025
Acclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser TechnologyAcclaro Medical, a pioneering medical technology company focused on developing cutting-edge solutions that improve patient care and redefine medical practices, proudly announces the successful completion of its Series B funding round. Led by Accelmed Partners with participation by existing investor 3E Bioventures Capital, the combined funding of $23 million marks a pivotal milestone in the company's journey to fulfill unmet aesthetic needs through its innovative 2910 nm fiber laser solution and other disruptive technologies.
Contact Us